SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.
© Tetiana Yurchenko/Shutterstock.com
Dapagliflozin: All-Cause & Cardiovascular Mortality
Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
Interesting T2DM: Diabetic Retinopathy & Drug News
Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.
Interesting T2DM: Peds Obesity & AHA Guides
Our February list includes updated guidelines for pediatric obesity, American Heart Assoc. statement on meal timing & frequency, and diabetes risks.
UTI Risk by Type of SGLT2 Inhibitor
The risk of urinary tract infections (UTIs), but not necessarily genital infections, may vary by agent within the SGLT2 inhibitor class.
Interesting T2DM: Neuropathy Care & Oral Tx Update
Our January list includes new care guidelines for neuropathy, updates to oral medication recommendations, and long-term RYGB outcomes for adolescents.
Top 10: Endocrinology Network 2016
SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and more – we’ve compiled a list of this year’s most popular articles on Endocrinology Network.
SGLT2 Inhibitors 2016: Year-End News Roundup
By clicking Accept, you agree to become a member of the UBM Medica Community.